Dynamic Control of Innate Antiviral Immunity in Skin Homeostasis and Inflammation
皮肤稳态和炎症中先天抗病毒免疫的动态控制
基本信息
- 批准号:10397558
- 负责人:
- 金额:$ 53.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-11 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAcyclovirAddressAntimicrobial ResistanceAntiviral AgentsAntiviral ResponseAntiviral resistanceAtopic DermatitisBindingBiological AssayBiteC FiberCaliberCellsClinicalCompetenceCuesCulicidaeCutaneousDendritic CellsElderlyEpidermisEpithelialEpithelial CellsFamily memberGenesGenetic TranscriptionGoalsHeterogeneityHomeostasisHost DefenseHumanIRF3 geneImmune systemImmunityImmunologicsIn VitroInflammationIntegration Host FactorsInterferon Type IInterferonsInterleukin-12Knockout MiceKnowledgeLigationLightMediatingModelingMolecularMusNatural ImmunityNerve FibersNeuronsNeurotransmittersNeutropeniaOperative Surgical ProceduresOutcomeParaplegiaPathway interactionsPatientsPharmacologyPlayPredispositionPreventionProductionProteinsRecombinant InterferonRegulationResistanceRoleSTAT1 geneSensorySignal PathwaySignal TransductionSkinSkin injurySpinal GangliaSystemTNF receptor-associated factor 3TestingTherapeuticToxic effectTraumaViralVirusVirus DiseasesWorkadaptive immune responseantimicrobialantiviral immunitydefined contributiongene inductionhigh riskin vivoinfection rateinnovationkeratinocyteknock-downloss of function mutationneonatenephrotoxicityneurosensorynew therapeutic targetnovelnovel therapeuticspathogenic viruspatient populationpreventprotein expressionreceptorrelating to nervous systemsingle cell sequencingtargeted treatmenttranscription factor
项目摘要
Project Summary
Loss-of-function mutations and suppression of innate antiviral proteins, such as OAS2 and OASL are associated with high
viral infection rates in mice and humans. Because of their induction by interferons, these antiviral proteins are often
referred to as interferon-stimulated genes (ISG). While recombinant interferon stimulates production of these antiviral
proteins, type I interferon’s severe toxicity is the major limitation in its therapeutic utility. Additionally, pharmacological
antivirals, such as acyclovir, have a high risk for triggering neutropenia and nephrotoxicity in vulnerable patient
populations. Therefore, there is a significant unmet clinical need for new antiviral therapeutics. This need can be
addressed by developing a full understanding of interferon-independent regulation of endogenous antiviral proteins and
identifying targets for therapy and prevention by activation of this incredibly potent natural antiviral pathway. Our
proposed work will answer important question: 1) Which interferon-independent signals and pathways can induce
antiviral competence? 2) Does epithelial antiviral innate immunity differ on a single cell level? 3) What factors
collaborate in the induction of innate antiviral immunity?
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer Yunyan Zhang其他文献
Jennifer Yunyan Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennifer Yunyan Zhang', 18)}}的其他基金
K63-Ubiquitin-mediated cell signal regulation in epidermis
K63-泛素介导的表皮细胞信号调节
- 批准号:
10379315 - 财政年份:2019
- 资助金额:
$ 53.41万 - 项目类别:
K63-Ubiquitin-mediated cell signal regulation in epidermis
K63-泛素介导的表皮细胞信号调节
- 批准号:
10596571 - 财政年份:2019
- 资助金额:
$ 53.41万 - 项目类别:
K63-Ubiquitin-mediated cell signal regulation in epidermis
K63-泛素介导的表皮细胞信号调节
- 批准号:
9903230 - 财政年份:2019
- 资助金额:
$ 53.41万 - 项目类别:
Dynamic Control of Innate Antiviral Immunity in Skin Homeostasis and Inflammation
皮肤稳态和炎症中先天抗病毒免疫的动态控制
- 批准号:
9924441 - 财政年份:2018
- 资助金额:
$ 53.41万 - 项目类别:
Dynamic Control of Innate Antiviral Immunity in Skin Homeostasis and Inflammation
皮肤稳态和炎症中先天抗病毒免疫的动态控制
- 批准号:
10686699 - 财政年份:2018
- 资助金额:
$ 53.41万 - 项目类别:
THE ROLE OF MALT1 IN MELANOMA GROWTH AND METASTASIS
Malt1 在黑色素瘤生长和转移中的作用
- 批准号:
9102022 - 财政年份:2015
- 资助金额:
$ 53.41万 - 项目类别:
JUN PROTEINS IN EPIDERMAL HOMEOSTASIS AND NEOPLASIA
Jun 蛋白在表皮稳态和肿瘤形成中的作用
- 批准号:
8131846 - 财政年份:2010
- 资助金额:
$ 53.41万 - 项目类别:
JUN PROTEINS IN EPIDERMAL HOMEOSTASIS AND NEOPLASIA
Jun 蛋白在表皮稳态和肿瘤形成中的作用
- 批准号:
8664734 - 财政年份:2010
- 资助金额:
$ 53.41万 - 项目类别:
JUN PROTEINS IN EPIDERMAL HOMEOSTASIS AND NEOPLASIA
Jun 蛋白在表皮稳态和肿瘤形成中的作用
- 批准号:
8272464 - 财政年份:2010
- 资助金额:
$ 53.41万 - 项目类别:
JUN PROTEINS IN EPIDERMAL HOMEOSTASIS AND NEOPLASIA
Jun 蛋白在表皮稳态和肿瘤形成中的作用
- 批准号:
7898983 - 财政年份:2010
- 资助金额:
$ 53.41万 - 项目类别:
相似海外基金
DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS
开发一种新型抗病毒药物来治疗和预防人眼疱疹性角膜炎的阿昔洛韦耐药性
- 批准号:
9255235 - 财政年份:2017
- 资助金额:
$ 53.41万 - 项目类别:
Establishment of rapid diagnosis system of acyclovir resistant varicella zoster virus
抗阿昔洛韦水痘带状疱疹病毒快速诊断系统的建立
- 批准号:
15K19594 - 财政年份:2015
- 资助金额:
$ 53.41万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Long-Term Herpes Simplex Virus-1 Suppression by Continuous Acyclovir Delivery
通过连续阿昔洛韦给药来长期抑制单纯疱疹病毒 1
- 批准号:
8101508 - 财政年份:2011
- 资助金额:
$ 53.41万 - 项目类别:
Sustained release acyclovir for prophylaxis of genital herpes
缓释阿昔洛韦预防生殖器疱疹
- 批准号:
7619774 - 财政年份:2009
- 资助金额:
$ 53.41万 - 项目类别:
INTRAVENOUS ACYCLOVIR TREATMENT FOR POSTHERPETIC NEURALGIA
静脉注射阿昔洛韦治疗带状疱疹后神经痛
- 批准号:
7377812 - 财政年份:2006
- 资助金额:
$ 53.41万 - 项目类别:
INTRAVENOUS ACYCLOVIR TREATMENT FOR POSTHERPETIC NEURALGIA
静脉注射阿昔洛韦治疗带状疱疹后神经痛
- 批准号:
7200592 - 财政年份:2005
- 资助金额:
$ 53.41万 - 项目类别:
SHEDDING AFTER BEGINNING ACYCLOVIR TREATMENT HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)
开始阿昔洛韦治疗 2 型单纯疱疹病毒 (HSV-2) 后脱落
- 批准号:
7198863 - 财政年份:2005
- 资助金额:
$ 53.41万 - 项目类别:














{{item.name}}会员




